Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal models (in vitro antibody development and animal models of MS and AD)
PubMed 30323343 · doi:10.1038/s41590-018-0232-x
What was done
Researchers developed a monoclonal antibody (5B8) directed against the cryptic fibrin epitope γ377-395 to block fibrin-mediated inflammation and oxidative stress while preserving normal clotting functions. They evaluated the antibody in cell assays for nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and proinflammatory gene expression, and tested its therapeutic delivery, target engagement, innate immune activation, and neurodegeneration outcomes in animal models of multiple sclerosis (MS) and Alzheimer's disease (AD).
What was found
The abstract reports no numerical values. It states that 5B8 suppressed fibrin-induced NADPH oxidase activation and proinflammatory gene expression. In animal models of MS and AD, systemically administered 5B8 entered the central nervous system, bound parenchymal fibrin, and reduced innate immune activation and neurodegeneration without interfering with coagulation.
Why it matters
Blood-brain barrier disruption causes fibrin deposition that drives neurotoxicity in multiple sclerosis and Alzheimer's disease. This study demonstrates a method to selectively neutralize fibrin-driven neuroinflammation without increasing systemic bleeding risks.
Limits
Findings are entirely derived from preclinical in vitro and animal models, which may not translate directly to human disease. The abstract provides no sample sizes, numerical effect sizes, or statistical metrics.
Cited by
- supports Researcher Katerina Akassoglou developed a therapeutic antibody that blocks the interaction between fibrinogen and microglia to prevent neuroinflammation.